Literature DB >> 33854208

G-protein subunit gamma-4 expression has potential for detection, prediction and therapeutic targeting in liver metastasis of gastric cancer.

Haruyoshi Tanaka1, Mitsuro Kanda2, Takashi Miwa1, Shinichi Umeda1, Koichi Sawaki1, Chie Tanaka1, Daisuke Kobayashi1, Masamichi Hayashi1, Suguru Yamada1, Goro Nakayama1, Masahiko Koike1, Yasuhiro Kodera1.   

Abstract

BACKGROUND: The liver is the most common site for haematogenous metastasis of gastric cancer, and liver metastasis is fatal.
METHODS: We conducted a transcriptomic analysis between metastatic foci in the liver, primary tumour and adjacent tissues from gastric cancer patients with metastasis limited to the liver. We determined mRNA expression levels in tumour tissues of 300 patients with gastric cancer via quantitative RT-PCR. The oncogenic phenotypes of GNG4 were determined with knockdown, knockout and forced expression experiments. We established and compared subcutaneous and liver metastatic mouse xenograft models of gastric cancer to reveal the roles of GNG4 in tumorigenesis in the liver.
RESULTS: GNG4 was upregulated substantially in primary gastric cancer tissues as well as liver metastatic lesions. High levels of GNG4 in primary cancer tissues were associated with short overall survival and the likelihood of liver recurrence. Functional assays revealed that GNG4 promoted cancer cell proliferation, the cell cycle and adhesiveness. Tumour formation by GNG4-knockout cells was moderately reduced in the subcutaneous mouse model and strikingly attenuated in the liver metastasis mouse model.
CONCLUSIONS: GNG4 expression may provide better disease monitoring for liver metastasis, and GNG4 may be a novel candidate therapeutic target for liver metastasis.
© 2021. The Author(s), under exclusive licence to Cancer Research UK.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33854208      PMCID: PMC8292368          DOI: 10.1038/s41416-021-01366-1

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  50 in total

Review 1.  Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines.

Authors:  Yasuhiro Kodera; Kazumasa Fujitani; Norimasa Fukushima; Seiji Ito; Kei Muro; Norifumi Ohashi; Takaki Yoshikawa; Daisuke Kobayashi; Chie Tanaka; Michitaka Fujiwara
Journal:  Gastric Cancer       Date:  2014-04       Impact factor: 7.370

2.  Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.

Authors:  Kohei Shitara; Mustafa Özgüroğlu; Yung-Jue Bang; Maria Di Bartolomeo; Mario Mandalà; Min-Hee Ryu; Lorenzo Fornaro; Tomasz Olesiński; Christian Caglevic; Hyun C Chung; Kei Muro; Eray Goekkurt; Wasat Mansoor; Raymond S McDermott; Einat Shacham-Shmueli; Xinqun Chen; Carlos Mayo; S Peter Kang; Atsushi Ohtsu; Charles S Fuchs
Journal:  Lancet       Date:  2018-06-04       Impact factor: 79.321

3.  Long-term outcomes of laparoscopy-assisted distal gastrectomy with suprapancreatic nodal dissection for clinical stage I gastric cancer: a multicenter phase II trial (JCOG0703).

Authors:  Naoki Hiki; Hitoshi Katai; Junki Mizusawa; Kenichi Nakamura; Mikihito Nakamori; Takaki Yoshikawa; Kazuyuki Kojima; Haruhiko Imamoto; Motoki Ninomiya; Seigo Kitano; Masanori Terashima
Journal:  Gastric Cancer       Date:  2017-01-16       Impact factor: 7.370

Review 4.  Gastric cancer.

Authors:  Eric Van Cutsem; Xavier Sagaert; Baki Topal; Karin Haustermans; Hans Prenen
Journal:  Lancet       Date:  2016-05-05       Impact factor: 79.321

5.  A randomized phase II multicenter trial to explore efficacy of weekly intraperitoneal in comparison with intravenous paclitaxel administered immediately after gastrectomy to the patients with high risk of peritoneal recurrence: final results of the INPACT trial.

Authors:  Naoto Takahashi; Mitsuro Kanda; Takaki Yoshikawa; Nobuhiro Takiguchi; Kazumasa Fujitani; Katsufumi Miyamoto; Yuichi Ito; Osamu Takayama; Motohiro Imano; Norio Mitsumori; Junichi Sakamoto; Satoshi Morita; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2018-03-13       Impact factor: 7.370

Review 6.  Genetics and Molecular Pathogenesis of Gastric Adenocarcinoma.

Authors:  Patrick Tan; Khay-Guan Yeoh
Journal:  Gastroenterology       Date:  2015-06-12       Impact factor: 22.682

7.  Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.

Authors:  Claudia Allemani; Tomohiro Matsuda; Veronica Di Carlo; Rhea Harewood; Melissa Matz; Maja Nikšić; Audrey Bonaventure; Mikhail Valkov; Christopher J Johnson; Jacques Estève; Olufemi J Ogunbiyi; Gulnar Azevedo E Silva; Wan-Qing Chen; Sultan Eser; Gerda Engholm; Charles A Stiller; Alain Monnereau; Ryan R Woods; Otto Visser; Gek Hsiang Lim; Joanne Aitken; Hannah K Weir; Michel P Coleman
Journal:  Lancet       Date:  2018-01-31       Impact factor: 79.321

Review 8.  Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival: Systematic Review and Pooled Analysis.

Authors:  Sheraz R Markar; Sameh Mikhail; George Malietzis; Thanos Athanasiou; Christophe Mariette; Mitsuru Sasako; George B Hanna
Journal:  Ann Surg       Date:  2016-06       Impact factor: 12.969

9.  Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial.

Authors:  Hironori Ishigami; Yoshiyuki Fujiwara; Ryoji Fukushima; Atsushi Nashimoto; Hiroshi Yabusaki; Motohiro Imano; Haruhiko Imamoto; Yasuhiro Kodera; Yoshikazu Uenosono; Kenji Amagai; Shigenori Kadowaki; Hiroto Miwa; Hironori Yamaguchi; Takuhiro Yamaguchi; Tempei Miyaji; Joji Kitayama
Journal:  J Clin Oncol       Date:  2018-05-10       Impact factor: 44.544

10.  The Evolutionary Origins of Recurrent Pancreatic Cancer.

Authors:  Hitomi Sakamoto; Marc A Attiyeh; Jeffrey M Gerold; Alvin P Makohon-Moore; Akimasa Hayashi; Jungeui Hong; Rajya Kappagantula; Lance Zhang; Jerry P Melchor; Johannes G Reiter; Alexander Heyde; Craig M Bielski; Alexander V Penson; Mithat Gönen; Debyani Chakravarty; Eileen M O'Reilly; Laura D Wood; Ralph H Hruban; Martin A Nowak; Nicholas D Socci; Barry S Taylor; Christine A Iacobuzio-Donahue
Journal:  Cancer Discov       Date:  2020-03-19       Impact factor: 38.272

View more
  4 in total

1.  Transcriptomic profiling on localized gastric cancer identified CPLX1 as a gene promoting malignant phenotype of gastric cancer and a predictor of recurrence after surgery and subsequent chemotherapy.

Authors:  Haruyoshi Tanaka; Mitsuro Kanda; Dai Shimizu; Chie Tanaka; Yoshikuni Inokawa; Norifumi Hattori; Masamichi Hayashi; Goro Nakayama; Yasuhiro Kodera
Journal:  J Gastroenterol       Date:  2022-06-21       Impact factor: 6.772

2.  Persistent Properties of a Subpopulation of Cancer Cells Overexpressing the Hedgehog Receptor Patched.

Authors:  Álvaro Javier Feliz Morel; Anida Hasanovic; Aurélie Morin; Chloé Prunier; Virginie Magnone; Kevin Lebrigand; Amaury Aouad; Sarah Cogoluegnes; Judith Favier; Claude Pasquier; Isabelle Mus-Veteau
Journal:  Pharmaceutics       Date:  2022-05-05       Impact factor: 6.525

3.  G-Protein Subunit Gamma 4 as a Potential Biomarker for Predicting the Response of Chemotherapy and Immunotherapy in Bladder Cancer.

Authors:  Lianhui Duan; Xuefei Liu; Ziwei Luo; Chen Zhang; Chun Wu; Weiping Mu; Zhixiang Zuo; Xiaoqing Pei; Tian Shao
Journal:  Genes (Basel)       Date:  2022-04-14       Impact factor: 4.141

4.  High GNG4 expression is associated with poor prognosis in patients with lung adenocarcinoma.

Authors:  Bodong Zhou; Wenbo Zhu; Shuai Yuan; Yifei Wang; Qing Zhang; Hong Zheng; Lei Zhu; Jie Xu
Journal:  Thorac Cancer       Date:  2021-12-23       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.